FibroGen Valuation
Is FGEN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FGEN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FGEN *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FGEN *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FGEN *?
Key metric: As FGEN * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is FGEN *'s PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | US$180.02m |
| Market Cap | US$39.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FGEN *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.3x | ||
4131 NeoCore Technology | 17.9x | n/a | NT$1.2b |
6645 Kim Forest Enterprise | 3.2x | n/a | NT$1.5b |
6539 DV Biomed | 0.9x | n/a | NT$1.4b |
MDG1 Medigene | 3x | 16.1% | €22.6m |
FGEN * FibroGen | 0.2x | -1.4% | Mex$39.0m |
Price-To-Sales vs Peers: FGEN * is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (6.3x).
Price to Sales Ratio vs Industry
How does FGEN *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: FGEN * is good value based on its Price-To-Sales Ratio (0.2x) compared to the Global Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is FGEN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FGEN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%
ICON
US$17.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%